Justine Ra is a healthcare reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing coverage on neurology and neurodegenerative diseases. Justine holds a degree in English from The University of Michigan, Ann Arbor.
The acquisition allows AbbVie to establish its presence in the ovarian cancer market with Immunogen’s Elahere.
A Phase IIb/III trial studying the company’s immunotherapy izokibep, failed to achieve statistical significance for its primary endpoint
Merz’s drug Xeomin is already approved by the FDA and EMA to treat chronic sialorrhea or excessive drooling.
NeoImmuneTech is developing NT-17, an IL-7 treatment, to promote rapid T-cell recovery in patients with acute radiation syndrome.
Augtyro (repotrectinib) is the only FDA-approved tumour kinase inhibitor (TKI) for ROS1-positive non-small cell lung cancer (NSCLC).
Give your business an edge with our leading industry insights.
Orphelia has lined its discovery pipeline with a number of pediatric CNS and rare cancer indications.
Amidst POINT’s shareholder turbulence, Lilly is keen to move forward with the $1.4bn acquisition.
Alfasigma will also gain access to Intercept’s severe alcohol-associated hepatitis (sAH) drug INT-787 currently in a Phase IIa study.
NRx gained FDA fast track designation for the development of NRX-100 as part of a treatment for acute suicidality.
As per the latest restructuring plan, Sangamo will advance its programs using AAV capsid delivery, Nav1.7 program, and Prion therapies.